The global markets of glucosamine have moved in opposite directions in the first half of October 2025. The nutraceutical manufacturers have accelerated their purchases to build glucosamine inventories for increased winter production runs of bone and joint supplements in the Asia Pacific market. The inventory dynamics have prompted the glucosamine suppliers to adopt strategic pricing and tighten available spot volumes. The markets in North America have entered the month with comfortable stocks after strategic procurement in previous months. The sufficient inventory has reduced the urgency to replenish which has exerted a downward pressure on US export quotes. The seasonal anticipation, inventory management choices and supplier allocation strategies have bifurcated the markets. ChemAnalyst expects that the glucosamine prices will likely firm globally as winter production demand persists and inventories at supplier and distributor levels will tighten further. The buyers and procurers should avoid panic spot buying and instead quantify realistic consumption for Q4 2025–Q1 2026.
